Synapse - Christopher Famulare

Results (49)

Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype

Journal Article

Galera, P.; Dilip, D.; Derkach, A.; Chan, A.; Zhang, Y.; Persaud, S.; Mishra, T.; Kramer, K.; Kathpalia, M.; Liu, Y.; more...
Blood (2025)

Fulltext@MSK | Save

HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML

Meeting Abstract

Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L.; more...
Blood (2024)

Fulltext@MSK | Save

Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center

Meeting Abstract

Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
Blood (2024)

Fulltext@MSK | Save

Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction

Meeting Abstract

Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
Blood (2024)

Fulltext@MSK | Save

Clinical Factors but not somatic mutations predict for survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplant: Analysis of the North American myelofibrosis transplant outcome (NAMTO) study

Meeting Abstract

Ajufo, H.; Derkach, A.; Rampal, R. K.; Famulare, C.; Nemirovsky, D.; Chervin, J.; Ho, V.; Gupta, V.; Viswabandya, A.; Deeg, H. J.; more...
Blood (2023)

Fulltext@MSK | Save

TP53 Y220C mutations in patients with myeloid malignancies

Meeting Abstract

Gener-Ricos, G.; Bewersdorf, J. P.; Loghavi, S.; Goldberg, A. D.; Famulare, C.; Issa, G. C.; Borthakur, G.; Kadia, T. M.; Carter, B. Z.; Patel, K. P.; more...
Blood (2023)

Fulltext@MSK | Save

Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia

Meeting Abstract

Sirenko, M.; Lee, S.; Sun, Z.; Chaligne, R.; Asimomitis, G.; Brierley, C. K.; Bernard, E.; Cai, S. F.; Myers, R. M.; Nadorp, B.; more...
Blood (2023)

Fulltext@MSK | Save

Despite high rates of remission, treatment of IDH-mutant AML with hypomethylating agents and venetoclax is associated with frequent treatment delays, modifications, and transfusions